Zealand Pharma stated Wednesday that its weight problems candidate that makes use of a novel mechanism led to notable weight reduction in an early trial.
Over 28 weeks, sufferers taking dapiglutide, which targets receptors of the GLP-1 and GLP-2 hormone, misplaced on common 11.6% of their weight, whereas these on placebo misplaced 0.2%.
The corporate urged the outcomes had been notably promising on condition that 95% of the individuals within the medical trial had been male. (Weight problems trials normally enroll extra girls, who are inclined to lose extra weight than males on medicines.) Moreover, the trial didn’t embrace any life-style modifications.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
